IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC Region
February 02 2022 - 7:00AM
IsoPlexis, the Superhuman Cell Company, today announced the opening
of its first office in the Asia-Pacific (APAC) region headed by
Jason Ou as President/General Manager, APAC Region. In this role,
Mr. Ou will further advance IsoPlexis' growth in the APAC region,
bolstered by a new office facility in Shanghai that will focus
primarily on sales and technical support.
Mr. Ou brings more than a decade of leadership, operational, and
commercial experience in the life sciences industry to IsoPlexis.
He joined IsoPlexis from Tecan, a global provider of automated
workflow solutions in the life science and clinical diagnostics
markets. Mr. Ou started at Tecan as the OEM Components Business
Manager for China & Southeast Asia, before becoming Director of
OEM Business for APAC. In his last position with Tecan, Mr. Ou was
Head of Market Unit Commercial Operations, Asia-Pacific.
"Jason joining our leadership team signals our commitment to
growing IsoPlexis’ international footprint in the APAC region,"
said Peter Siesel, Chief Commercial Officer of IsoPlexis. "His
extensive track record of leadership, solution-oriented thinking,
and customer satisfaction in the life sciences industry all align
with our plans for APAC expansion. We are confident that his
leadership, along with the opening of our new office in Shanghai,
will help IsoPlexis to continue its rapid global growth and
innovation.”
The direct office in Shanghai, located in the New Bund Oriental
Plaza Phase I, has 5000 square feet of office space dedicated to
supporting the APAC commercial organization with sales, technical
support, and other general operations. In addition, IsoPlexis has
already opened four service labs in four of China’s largest cities:
Shanghai, Beijing, Guangzhou, and Shenzhen. These service labs
offer both support and test services on the IsoPlexis platform as
well as demonstrations of the platform.
“IsoPlexis’ incredible single-cell proteomics technology has the
potential to accelerate advanced medicines, and I’m excited and
proud to be part of the journey,” said Jason Ou. “As APAC research
continues to expand, I am looking forward to working with this
extraordinarily talented team to bring such groundbreaking
technology into the region.”
ABOUT ISOPLEXIS:
IsoPlexis is the Superhuman Cell company.
IsoPlexis’ systems uniquely identify a comprehensive range of
multifunctional single cells, i.e. the superhero cells in the human
body. These cells enable researchers to understand and predict
disease progression, treatment resistance and therapeutic efficacy
to advance all of human health.
IsoPlexis has been named Top Innovation or Design by The
Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple
others. The IsoPlexis platform is used globally by researchers,
including those at the top 15 global pharmaceutical companies and
at two-thirds of leading U.S. comprehensive cancer centers.
Cautionary Note Regarding Forward Looking
StatementsCertain statements in this press release are
forward-looking statements that are subject to risks and
uncertainties that could cause results to be materially different
than expectations. Such statements can be identified by the use of
words such as "will", “signal”, “confident”, “potential”, “forward”
and “bring” . Important factors that could cause actual
results to differ materially include: the rate of adoption of the
Company's technology by its customers and potential customers as
well as the risk factors set forth in the Risk Factors section of
the Company's prospectus filed with the SEC. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, IsoPlexis
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
http://www.isoplexis.com
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jun 2024 to Jul 2024
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jul 2023 to Jul 2024